Data regarding the participation of the RAAS in hypertension pathophysiology in the SHR are driven mainly by the impact of targeted inhibition of the presumably deleterious classical ACE/Ang II/AT1R pathway [17] or by activation of the supposedly beneficial alternative ACE2/Ang 1-7/MasR pathway [18,19]. The gene discussed is MAS1L; the disease is Hypertension.